NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders-medium-term follow-up and clinical course.
B Nelson, GP Amminger, HP Yuen, C Markulev, S Lavoie, MR Schäfer, JA Hartmann, N Mossaheb, M Schlögelhofer, S Smesny, IB Hickie, G Berger, EYH Chen, L de Haan, DH Nieman, M Nordentoft, A Riecher-Rössler, S Verma, A Thompson, AR Yung Show all
NPJ Schizophr | Published : 2018
This study reports a medium-term follow-up of a randomised, double-blind, placebo-controlled trial of omega-3 polyunsaturated fatty acids (PUFA) in ultra-high risk for psychosis (UHR) patients. Primary outcomes of interest were transition to psychosis and symptomatic and functional outcome. A secondary aim was to investigate clinical predictors of medium-term outcome. Three hundred four UHR participants were recruited across 10 specialised early psychosis services in Australia, Asia, and Europe. The intervention consisted of 1.4 g/daily of omega-3 PUFA or placebo, plus up to 20 sessions of cognitive-behavioural case management (CBCM), over the 6-month study period, with participants receivin..View full abstract
Awarded by Department of Health